Multiple sclerosis trials in Italy

In Italy 54 Also abroad 503

54 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Where
Catania, Cefalu', Chieti Scalo, Florence, Messina, Milan, Naples, Orbassano, Pozzilli, Rome
Age
18 years to 60 years
People
990 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00
No phaseTaking people
Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices
Where
Messina
Age
18 years to 70 years
People
150
Run by
IRCCS Centro Neurolesi Bonino Pulejo
See details and how to joinNCT07066137
Phase 3Taking people
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Where
Catania, Cefalu', Chieti Scalo, Genoa, Milan, Naples, Orbassano, Pozzilli, Rome
Age
18 years to 60 years
People
705 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00
Phase 3Taking people
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
Where
Chieti, Como, Florence, Foggia, Milan, Monza, Palermo, Pozzilli, Rome, Verona
Age
18 years to 64 years
People
386 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00
Phase 3Taking people
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Where
Bergamo, Foggia, Genoa, Milan, Pavia, Rome
Age
40 years to 70 years
People
400 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00
Phase 3Taking people
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Where
Bologna, Catania, Cefalu', Florence, Milan, Naples, Rome, Siena
Age
18 years to 64 years
People
125 worldwide
Run by
Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00
Phase 2Taking people
Foetal neural stem cells transplantation in progressive multiple sclerosis
Where
Bergamo, Como, Milan, Monza, Pavia
Age
18 years and over
People
86
Run by
Ospedale San Raffaele S.r.l.
See details and how to join2024-511028-15-00 · EU 2024-511028-15-00
No phaseNot yet taking people in Italy
Dual-Task Balance Training in People With Multiple Sclerosis: a Randomized Feasibility Study
Where
Verona
Age
18 years to 75 years
People
30
Run by
Universita di Verona
See details and how to joinNCT07878702
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Ancona, Bergamo, Chieti, Foggia, Gallarate, Naples, Pavia, Pozzilli, Roma
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 3Taking people
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Where
Cagliari, Foggia, Milan, Modena, Parma, Perugia, Rome, Rozzano, Verona
Age
18 years to 60 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00
No phaseNot yet taking people in Italy
Bridging Gaps in the Multidimensional Assessment and Management of Overlapping Symptoms in Multiple Sclerosis and Functional Motor Disorders: Prevalence and Rehabilitation Effectiveness
Where
Milan, Verona
Age
18 years and over
People
192
Run by
IRCCS San Raffaele
See details and how to joinNCT07856485
Phase 2Taking people
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Where
Chieti Scalo, Genoa, Milan, Naples, Pavia, Rome, Salerno
Age
18 years to 60 years
People
360 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00
Phase 3Taking people
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Where
Naples, Rome
Age
Up to 17 years
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00
Phase 3Taking people
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Where
Milan, Naples, Rome
Age
10 years to 17 years
People
194 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06408259 · EU 2022-501332-42-00
Phase 2Taking people
A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis
Where
Cefalu', Florence, Montichiari, Pozzilli, Rome
Age
18 years to 64 years
People
93 worldwide
Run by
Zenas Biopharma (USA) LLC
See details and how to join2024-512707-40-00 · EU 2024-512707-40-00
Phase 3Taking people
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
Where
Ancona, Bergamo, Cagliari, Chieti Scalo, Foggia, Gallarate (VA), Naples, Orbassano, Pavia, Pozzilli, Rome
Age
18 years and over
People
677 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00
No phaseTaking people
Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)
Where
Milan
Age
18 years and over
People
1,050
Run by
IRCCS San Raffaele
See details and how to joinNCT07720765
No phaseTaking people
Sonification Techniques for Gait Training
Where
Pavia
Age
Up to 80 years
People
120
Run by
Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT04876339
Phase 4Taking people
Effects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsingremitting multiple sclerosis: correlation with disease activity, cognition, fatigue,depression and quality of life
Where
Milan
Age
18 years to 64 years
People
30
Run by
Ospedale San Raffaele S.r.l.
See details and how to join2024-513960-24-00 · EU 2024-513960-24-00
No phaseTaking people
ATLG Levels in Autologous HSCT for Multiple Sclerosis
Where
Milan
Age
18 years and over
People
20
Run by
Ciceri Fabio
See details and how to joinNCT07635693
No phaseEnrolling by invitation
The Italian Multiple Sclerosis and Related Disorders Register
Where
Genova
People
96,000
Run by
Fondazione Italiana Sclerosi Multipla
See details and how to joinNCT07636876
No phaseNot yet taking people in Italy
Evaluation of the Impact of Virtual Park on Training Motivation in Adult Patients
Where
Bari, Costa Masnaga, Milan, Montescano, Pavia, Pisa, Telese Terme
Age
18 years and over
People
70
Run by
Marta Mondellini
See details and how to joinNCT07616050
No phaseNot yet taking people in Italy
Olfactory and Trigeminal Functions in Patients With Multiple Sclerosis: Case-control Study
Where
Catania
Age
18 years to 55 years
People
200
Run by
University of Catania
See details and how to joinNCT06020937
No phaseTaking people
Auditory Functions in Patients With Multiple Sclerosis
Where
Catania
Age
20 years to 40 years
People
30
Run by
University of Catania
See details and how to joinNCT06164483
No phaseTaking people
Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis
Where
Naples, Telese Terme
Age
18 years and over
People
60
Run by
Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT05748015